CTI's Pixuvri gets NICE second chance and wins Italian OK
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has put on hold a decision not to recommend NHS funding for Cell Therapeutics' Pixuvri (pixantrone) because, in a bid to make the drug more cost-effective, the company has submitted a patient access scheme.